STOCK TITAN

ImmuCell fixes link to Q3 2026 earnings release

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K/A

Rhea-AI Filing Summary

ImmuCell Corporation (ICCC) amended its report to replace a broken hyperlink to the November 12, 2026 earnings release. The release reported third-quarter product sales rose 46.0% to $8.040 million from $5.506 million a year earlier; the comparison was aided in part by the absence of distributor-restocking headwinds in 2025. Net income was $953,000, versus a $140,000 net loss in the prior-year quarter. Gross margin was 44.2%, 130 basis points above the prior-year quarter, and adjusted EBITDA was $1.884 million, compared with $750,000.

Cash and cash equivalents were $7.914 million as of September 30, 2026, compared with $3.807 million as of December 31, 2025. Management said ImmuCell terminated its at-the-market offering given its strong cash position and expects to sign a negotiated $3 million line of credit during Q4 2026.

4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointThird-quarter revenue rose 46.0% to $8.040 million year over year.
  • Moderate pointThird-quarter net income was $953,000, versus a $140,000 net loss in 2025.
  • Moderate pointThird-quarter adjusted EBITDA was $1.884 million, compared with $750,000 in 2025.
  • Moderate pointNine-month operating cash flow was $7.348 million, versus $1.993 million in 2025.

Negative

  • None.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Product sales $8.040 million Three months ended September 30, 2026; $5.506 million in the same 2025 period; up 46.0%.
Net income $953,000 Three months ended September 30, 2026; compared with a $140,000 net loss in the same 2025 period.
Gross margin 44.2% Third quarter 2026; 130 basis points above the same 2025 period.
Adjusted EBITDA $1.884 million Three months ended September 30, 2026; $750,000 in the same 2025 period.
Net income $4.729 million Nine months ended September 30, 2026; $1.809 million in the same 2025 period.
Operating cash flow $7.348 million Nine months ended September 30, 2026; $1.993 million in the same 2025 period.
Cash and cash equivalents $7.914 million As of September 30, 2026; $3.807 million as of December 31, 2025.
Line of credit $3 million Negotiated with the company's bank; management expects to sign during Q4 2026.
Adjusted EBITDA financial
"We calculate adjusted EBITDA as described in the following table"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
non-GAAP financial measure financial
"The non-GAAP measures included in this press release"
A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.
At-The-Market offering financial
"we have terminated our At-The-Market offering"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
out-the-door volume financial
"distributor out-the-door volume growth of 18% over 2025"
colostrum-derived antibodies medical
"colostrum-derived, orally delivered antibodies"
Product sales $8.040 million Up 46.0% from $5.506 million in the same 2025 period
Net income $953,000 Compared with a $140,000 net loss in the same 2025 period
Gross margin 44.2% 130 basis points above the same 2025 period
Adjusted EBITDA $1.884 million Compared with $750,000 in the same 2025 period
Guidance

Management expects to sign a negotiated $3 million line of credit during Q4 2026; capacity-expansion and colostrum-sourcing efforts are projected to be completed on time and within budget.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did ICCC report in Q3 2026?

Product sales rose 46.0% to $8.040 million from $5.506 million in Q3 2025. The comparison was aided in part by the absence of distributor-restocking headwinds that affected the prior-year quarter.

Did ICCC make a profit in Q3 2026?

ImmuCell reported net income of $953,000 for Q3 2026, compared with a net loss of $140,000 in Q3 2025.

How did ICCC's distributor out-the-door volume change?

Distributor out-the-door volume grew 18% over 2025, according to the company's sales and marketing executive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 8-K/A date of report 11-12-26 true 0000811641 0000811641 2026-11-12 2026-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K/A
(Amendment No. 1)
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 12, 2026
 
 
ImmuCell Corporation
(Exact name of registrant as specified in its charter)
 
 
DE
 
001-12934
 
01-0382980
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
56 Evergreen Drive Portland, Maine
 
04103
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code 207-878-2770
 
 
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.10 par value per share
 
ICCC
 
The NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

Explanatory Note
 
On November 13, 2026, ImmuCell Corporation (the “Company) filed a Current Report on Form 8-K that was intended to include (as Exhibit 99.1) a copy of the Company's earnings release issued November 12, 2026. The Company later discovered that the hyperlink set forth in Exhibit 99.1 of that report produces an error message instead of the press release. The Company is filing this Amendment No. 1 on Form 8-K/A solely in order to provide a working hyperlink to that exhibit. The exhibit is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934.
 
 
 

 
 
Item 9.01.  Exhibits.
 
(d)           Exhibits.
 
 
 
99.1
Press Release of the Company dated November 12, 2026
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 

 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
IMMUCELL CORPORATION
 
 
Date: November 19, 2026
By:
/s/ Timothy C. Fiori
 
 
Timothy C. Fiori
 
 
Chief Financial Officer
 

 
Exhibit Index
 
 
Exhibit No.
Description
99.1
99.1 Press Release of the Company dated November 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

Exhibit 99.1

ImmuCell


                  

ImmuCell Announces Unaudited Financial Results for

the Quarter Ended September 30, 2026

 

For Immediate Release

 

PORTLAND, Maine – November 12, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended September 30, 2026.

 

Management’s Discussion:

 

“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025. Gross margin was 44.2% in the third quarter of 2026, which is 130 basis points higher than the third quarter of 2025 and reflects higher pricing and manufacturing execution partially offset by the previously discussed shift of certain product development expenses to costs of goods sold.”

 

“We are pleased with our third quarter revenue and with distributor out-the-door volume growth of 18% over 2025,” commented Bobbi Jo Brockmann, Senior Vice President of Sales & Marketing. “Growth remained broad-based across our sales territories and product lines, supported by an increase in sales activity and continued progress in customer acquisition. We are also encouraged by inventory levels heading into our peak season as we shift our focus to the cow-calf market.”

 

“ImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions,” said Olivier te Boekhorst, President and CEO. “Increased commercial activity was supported by increased output from the manufacturing team. We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.”

 

“We have negotiated a new, larger $3 million line of credit with our bank, which we expect to sign during the fourth quarter of 2026,” continued Mr. Fiori. “Additionally, given our strong cash position, we have terminated our At-The-Market offering.”

 


 

Certain Financial Results:

 

 

●

Third quarter 2026 product sales increased 46.0%, to approximately $8.0 million, compared to the quarter ended September 30, 2025.

 

●

Third quarter 2026 gross margin increased to 44.2% of product sales compared to 42.9% during the quarter ended September 30, 2025.

 

●

Net income was $953,000, or $0.10 per diluted share, during the quarter ended September 30, 2026, compared to a net loss of $140,000, or ($0.02) per basic share, during the quarter ended September 30, 2025.

 

●

Adjusted EBITDA (calculation methodology shown below) was $1.9 million in the three months ended September 30, 2026, as compared to $0.8 million in the three months ended September 30, 2025.

 

 

Balance Sheet Data as of September 30, 2026:

 

 

●

Cash and cash equivalents increased to $7.9 million as of September 30, 2026, from $3.8 million as of December 31, 2025, such increase benefiting in part from the $2 million settlement payment received in May 2026.

 

●

Net working capital increased to approximately $16.9 million as of September 30, 2026 from $13.0 million as of December 31, 2025.

 

●

Stockholders’ equity increased to $32.8 million as of September 30, 2026 from $27.1 million as of December 31, 2025.

 


 

Condensed Statements of Income (Unaudited)

 

​

​

Three Months Ended September 30,

​

​

Nine Months Ended September 30,

​

(In thousands, except per share amounts)

​

2026

​

​

2025

​

​

2026

​

​

2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Product sales

​

$

8,040

​

​

$

5,506

​

​

$

25,584

​

​

$

20,018

​

Costs of goods sold

​

​

4,485

​

​

​

3,143

​

​

​

14,934

​

​

​

11,483

​

Gross profit

​

​

3,555

​

​

​

2,363

​

​

​

10,650

​

​

​

8,535

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Sales, marketing and administrative expenses

​

​

2,420

​

​

​

1,649

​

​

​

7,174

​

​

​

4,545

​

Product development expenses

​

​

177

​

​

​

694

​

​

​

614

​

​

​

2,283

​

Other operating income

​

​

-

​

​

​

-

​

​

​

(2,000

)

​

​

-

​

Operating expenses

​

​

2,597

​

​

​

2,343

​

​

​

5,788

​

​

​

6,828

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

NET OPERATING INCOME

​

​

958

​

​

​

20

​

​

​

4,862

​

​

​

1,707

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Other (expenses) income, net

​

​

(22

)

​

​

(155

)

​

​

(92

)

​

​

110

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

INCOME (LOSS) BEFORE INCOME TAXES

​

​

936

​

​

​

(135

)

​

​

4,770

​

​

​

1,817

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Income tax (benefit) expense

​

​

(17

)

​

​

5

​

​

​

41

​

​

​

8

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

NET INCOME (LOSS)

​

$

953

​

​

$

(140

)

​

$

4,729

​

​

$

1,809

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic weighted average common shares outstanding

​

​

9,084

​

​

​

9,046

​

​

​

9,065

​

​

​

9,019

​

Basic net income (loss) per share

​

$

0.10

​

​

$

(0.02

)

​

$

0.52

​

​

$

0.20

​

Diluted weighted average common shares outstanding

​

​

9,298

​

​

​

9,046

​

​

​

9,189

​

​

​

9,019

​

Diluted net income (loss) per share

​

$

0.10

​

​

$

(0.02

)

​

$

0.51

​

​

$

0.20

​

 

 

Selected Balance Sheet Data (In thousands) (Unaudited)

 

​

​

As of

​

​

As of

​

​

​

September 30, 2026

​

​

December 31, 2025

​

​

​

​

​

​

​

​

​

​

Cash and cash equivalents

​

$

7,914

​

​

$

3,807

​

Inventory

​

$

9,857

​

​

$

9,267

​

Net working capital

​

$

16,897

​

​

$

12,967

​

Total assets

​

$

47,958

​

​

$

42,532

​

Stockholders' equity

​

$

32,774

​

​

$

27,055

​

 

Selected Cash Flow Data (In thousands) (Unaudited)

 

​

​

Nine Months Ended September 30,

​

​

​

2026

​

​

2025

​

Operating Activities

​

$

7,348

​

​

$

1,993

​

Investing Activities

​

​

(2,247

)

​

​

(1,047

)

Financing Activities

​

​

(994

)

​

​

(818

)

Net Change in Cash

​

​

4,107

​

​

​

128

​

Cash at Beginning of Period

​

​

3,807

​

​

​

3,758

​

Cash at End of Period

​

$

7,914

​

​

$

3,886

​

 


 

Non-GAAP Financial Measures: Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flow that either excludes or includes amounts that are not normally included in or excluded from the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP measures included in this press release should be considered in addition to, and not as a substitute for or superior to, the comparable measure prepared in accordance with GAAP.

 

We believe that considering the non-GAAP measure of Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) assists management and investors by looking at our performance across reporting periods on a consistent basis excluding certain charges from our reported income before income taxes. We calculate adjusted EBITDA as described in the following table and reconciled to the most comparable GAAP financial measure:

 

​

​

Three Months Ended September 30,

​

​

Nine Months Ended September 30,

​

(In thousands)

​

2026

​

​

2025

​

​

2026

​

​

2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net income (Loss)

​

$

953

​

​

$

(140

)

​

$

4,729

​

​

$

1,809

​

Income tax (benefit) expense

​

​

(17

)

​

​

4

​

​

​

41

​

​

​

8

​

Interest expense (excluding debt issuance and debt discount costs)

​

​

89

​

​

​

105

​

​

​

278

​

​

​

336

​

Depreciation

​

​

459

​

​

​

674

​

​

​

1,458

​

​

​

2,009

​

Amortization (including debt issuance and debt discount costs)

​

​

3

​

​

​

34

​

​

​

9

​

​

​

66

​

Stock-based compensation expense

​

​

397

​

​

​

73

​

​

​

774

​

​

​

192

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Adjusted EBITDA

​

$

1,884

​

​

$

750

​

​

$

7,289

​

​

$

4,420

​

 

Cash payments to satisfy debt repayment obligations and to make capital expenditure investments are other uses of cash that are not included in the calculation of EBITDA, but which management also does consider when assessing its cash flows.

 

Webcast / Conference Call:
 

The Company is planning to host a conference call and webcast on November 13, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international). 

 

The live webcast can be accessed at: https://app.webinar.net/JL8AEda3K5D

 

The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/

 

A teleconference replay of the conference call will be available through November 20, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #2589057.

 

About ImmuCell:
 

ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at:

http://www.immucell.com/investors.

 


 

Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):

This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to:

 

 

●

our business plans, goals and strategies;

 

●

projections of future financial and operational performance, expense ratios and margins;

 

●

future demand for our products, including the First Defense® product line;

 

●

the sequence, duration, costs and goals of our program to repurpose our former Re-Tain® facility and equipment for First Defense® production; cost recoveries on Re-Tain® equipment no longer in service; and other elements of projected depreciation expense affecting future income for book and tax return purposes;

 

●

capital expenditures, contractual commitments, and the anticipated sources and uses of cash to fund them;

 

●

anticipated timing and terms of a new line of credit;

 

and any other statements that are not historical facts. projections about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not historical facts. These statements reflect management’s current expectations as of the date hereof, are based on management’s estimates, projections, beliefs and assumptions as of such date; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to differ materially, including risks relating to: competition in our markets; customer acceptance and product performance; alignment between our manufacturing resources and product demand; supply chain disruptions affecting our operations and our customer and supplier relationships; the commercial and operational risks of our current and planned expansion of production capacity; difficulties or delays in development, testing, regulatory approval, production and marketing of our products, and other risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission (SEC), including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. There can be no assurance that the risks or developments we anticipate will be those that actually affect us. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise.

 

 

Contacts:

Olivier te Boekhorst, President and CEO
Timothy C. Fiori, Chief Financial Officer
ImmuCell Corporation
investor.relations@immucell.com

 

 

Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
iccc@lythampartners.com

 

Filing Exhibits & Attachments

5 documents

Keep reading